ArticleJAMA health forum2025
Nicotine Reduction Standard in Cigarettes and Estimated Lives Saved and Deaths Averted.
Article in JAMA health forum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Compensatory Smoking With Very Low Nicotine Content Cigarettes: A Systematic Review and Meta-Analysis.JAMA network open · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: A potential policy that has been receiving substantial attention is a nicotine reduction standard (NRS) in cigarettes and other select combusted tobacco products. In 2025, the policy moved to the next phase required for future implementation, which entailed opening the policy to public comment. To date, the significance of this standard has been estimated only for the overall US population. Objective: To estimate the significance of an NRS by race and ethnicity, rural vs urban residence, and sex. Design, Setting, and Participants: The adaptive dynamic simulation model assumed enactment of an NRS in 2025 and was parameterized with population-specific inputs from the 2014 to 2015 and/or 2018 to 2019 Tobacco Use Supplement of the Current Population Survey and the CDC WONDER online database through the National Center for Health Statistics. It was assumed that the proportional association of an NRS with smoking cessation rates across populations would be the same and that those associations would be observed immediately (ie, in 2025). Twenty-four scenarios were simulated that varied the associations of nicotine reduction with the smoking cessation rate for each population (100%, 113%, and 200% increase) and the persistence of those associations (indefinitely or linearly increasing to 80% annual cessation after 25 years) using 4 background initiation rates (baseline, half of the population's baseline value, 5%, and 0%). Main Outcomes: Life-years saved (LYS) and premature deaths averted (PDA) by 2100. Results: In the scenario with maximal benefits (total LYS: 62 029 200; total PDA: 2 429 900), American Indian or Alaska Native persons gained 1 059 049 LYS and 43 878 PDA, Asian persons gained 894 537 LYS and 33 534 PDA, Black or African American persons gained 10 381 540 LYS and 421 914 PDA, Hispanic persons gained 9 422 976 LYS and 370 373 PDA, and rural residents gained 15 459 437 LYS and 637 993 PDA. For all or most scenarios, American Indian and Alaska Native individuals (0.5% of the population; 1.8% of PDAs based on the maximum scenario), Black/African American individuals (11.7% of the population; 15.2% of PDAs), and rural residents (20.0% of population; 26.3% of PDAs) gained a greater proportion of LYS and PDA than would be expected based on their proportional share of the US population. Large benefits were also estimated for White persons, individuals of both sexes, and urban-residing persons. Conclusions and Relevance: The study results suggest that an NRS may serve as a disparity-reducing policy in addition to offering broad, population-wide benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.